Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
ARYx Therapeutics, Inc. (ARYX)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
27.6
|
M
| |
|
|
| Market cap: |
$63.5
|
k
| |
|
|
|
Net debt:
|
$8.62
|
M
| |
|
|
|
EV:
|
$8.68
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
| Date Filed | Type | Description |
| 04/11/2011 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 04/08/2011 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 03/31/2011 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| 03/29/2011 |
25
| Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities |
| 03/22/2011 |
8-K
| Quarterly results |
| 03/21/2011 |
SC 13D/A
| Growth Equity Opportunities Fund, LLC has filed a Schedule 13D for ARYx Therapeutics, Inc. |
| 03/14/2011 |
4
| Growth Equity Opportunities Fund, LLC (10% Owner) has filed a Form 4 on ARYx Therapeutics, Inc. |
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| Revenues | 19.7 | 4.2 | 4.7 | -0.7 |
| Revenue growth | 374.4% | -12.3% | -806.3% | |
| Cost of goods sold | 0.2 | 0.3 | 2.1 | -28.2 |
| Gross profit | 19.5 | 3.9 | 2.6 | 27.5 |
| Gross margin | 98.8% | 93.7% | 55.3% | -4098.1% |
| Selling, general and administrative | 9.8 | 7.7 | 6.9 | 5.7 |
| Research and development | 40.1 | 25.0 | 24.0 | 22.5 |
| EBIT | -30.4 | -28.8 | -28.3 | -28.2 |
| EBIT margin | -154.2% | -692.6% | -596.9% | 4198.1% |
| Pre-tax income | 0.0 | 0.0 | 0.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 0.0 | 0.0 | 0.0 | 0.0 |
| Net margin | -0.2% | -0.7% | -0.6% | 4.2% |
| |
| Diluted EPS | ($1,646.17) | ($8,237.00) | ($26,844.79) | ($30,729.67) |
| Shares outstanding (diluted) | 0.0 | 0.0 | 0.0 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|